Shigeki Yagyu

kyoto prefectural university of medicine

H指数:21

被引数:1,772

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A potent and selective PHOX2B promoter-driven oncolytic adenovirus for targeted neuroblastoma therapy

强效且特异性的PHOX2B启动子驱动的溶瘤腺病毒，用于靶向神经母细胞瘤治疗

BIOMEDICINE & PHARMACOTHERAPY

IF7.5

2026-06-240

OAAI

Bispecific Ligand-Based EphB4 CAR-T Cells Generated Using Ephrin-B2 Show Potent Antitumor Activity Against Lung Adenocarcinoma

双特异性配体介导的EphB4 CAR-T细胞通过Ephrin-B2生成，对肺腺癌显示出强大的抗肿瘤活性

Cancer Science

IF4.3

2026-04-210

Alectinib boosts anti-tumor efficacy of disialoganglioside 2 chimeric antigen receptor T cells in ALK-mutated neuroblastoma by suppressing programmed death-ligand 1

Alectinib通过抑制程序性死亡配体1，增强双唾液酸神经节苷脂2嵌合抗原受体T细胞在ALK突变神经母细胞瘤中的抗肿瘤效果。

British Journal of Cancer

IF6.8

2026-03-230

PRE

Trial in progress: phase I study of non-viral gene-modified CAR-T cell therapy for malignant solid tumors expressing EPHB4 receptor (CARTiEr)

试验进行中：表达EPHB4受体的恶性实体瘤的非病毒基因修饰CAR-T细胞疗法I期研究（CARTiEr）

Frontiers in Oncology

IF3.3

2025-08-070

Feasibility of Intratumoral Administration With EPHB4-CAR-T Cells for the Treatment of Oral Squamous Cell Carcinoma

使用EPHB4-CAR-T细胞进行肿瘤内给药治疗口腔鳞状细胞癌的可行性

CANCER SCIENCE

IF4.3

2025-03-030

OAAI

Selective JAK2 Pathway Inhibitor, CHZ868, Ameriorates Anti-Leukemic Functionaliry in CD19 CAR-T Cells

选择性JAK2通路抑制剂，CHZ868，改善了CD19 CAR-T细胞的抗白血病功能。

BLOOD

IF23.1

2024-11-050

PRE

Low blood level of tumour suppressor miR-5193 as a target of immunotherapy to PD-L1 in gastric cancer

BRITISH JOURNAL OF CANCER

IF6.8

2023-12-263

PRE

Ligand-based, piggyBac-engineered CAR-T cells targeting EGFR are safe and effective against non-small cell lung cancers

MOLECULAR THERAPY ONCOLYTICS

IF5.3

2023-12-014

OAAI

Ligand-based, piggyBac-engineered CAR-T cells targeting EGFR are safe and effective against non-small cell lung cancers (vol 31, pg 1, 2023)

MOLECULAR THERAPY ONCOLYTICS

IF5.3

2023-12-011

OAAI

Biological characteristics of the leukemia-associated transcriptional factor AML1 disclosed by hematopoietic rescue of AML1-deficient embryonic stem cells by using a knock-in strategy

MOLECULAR AND CELLULAR BIOLOGY

IF2.7

2023-03-2865

OAAI

In ovo chorioallantoic membrane assay as a xenograft model for pediatric rhabdomyosarcoma

ONCOLOGY REPORTS

IF3.9

2023-03-023

OAAI

PiggyBac Transposon-Mediated CD19 Chimeric Antigen Receptor-T Cells Derived From CD45RA-Positive Peripheral Blood Mononuclear Cells Possess Potent and Sustained Antileukemic Function

FRONTIERS IN IMMUNOLOGY

IF5.9

2022-01-2712

OAAI

Reduced B7-H3 expression by PAX3-FOXO1 knockdown inhibits cellular motility and promotes myogenic differentiation in alveolar rhabdomyosarcoma

SCIENTIFIC REPORTS

IF3.9

2021-09-229

OAAI

Development of non-viral, ligand-dependent, EPHB4-specific chimeric antigen receptor T cells for treatment of rhabdomyosarcoma

MOLECULAR THERAPY-ONCOLYTICS

IF0

2021-03-0123

OAAI

The Novel Histone Deacetylase Inhibitor, OBP-801, Induces Apoptosis in Rhabdoid Tumors by Releasing the Silencing of NOXA

MOLECULAR CANCER THERAPEUTICS

IF5.5

2020-10-026

OAAI

Oncogenic role of HMGA2 in fusion-negative rhabdomyosarcoma cells

CANCER CELL INTERNATIONAL

IF6

2020-05-2410

OAAI

OBP-801, a novel histone deacetylase inhibitor, induces M-phase arrest and apoptosis in rhabdomyosarcoma cells (vol 41, pg 643, 2019)

ONCOLOGY REPORTS

IF3.9

2019-02-010

OAAI

OBP-801, a novel histone deacetylase inhibitor, induces M-phase arrest and apoptosis in rhabdomyosarcoma cells

ONCOLOGY REPORTS

IF3.9

2018-10-228

OAAI

MET/ERK2 pathway regulates the motility of human alveolar rhabdomyosarcoma cells

ONCOLOGY REPORTS

IF3.9

2016-11-0212

3D modeling of human cancer: A PEG-fibrin hydrogel system to study the role of tumor microenvironment and recapitulate the in vivo effect of oncolytic adenovirus

BIOMATERIALS

IF12.9

2016-04-0157

PREAI

Shigeki Yagyu

个人简介

教育背景

工作经历

荣誉奖项

研究方向